ID   HMOX1_HUMAN             Reviewed;         288 AA.
AC   P09601;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1989, sequence version 1.
DT   10-MAY-2017, entry version 183.
DE   RecName: Full=Heme oxygenase 1;
DE            Short=HO-1;
DE            EC=1.14.14.18 {ECO:0000250|UniProtKB:O48782};
GN   Name=HMOX1; Synonyms=HO, HO1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3345742; DOI=10.1111/j.1432-1033.1988.tb13811.x;
RA   Yoshida T., Biro P., Cohen T., Mueller R.M., Shibahara S.;
RT   "Human heme oxygenase cDNA and induction of its mRNA by hemin.";
RL   Eur. J. Biochem. 171:457-461(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT HIS-7.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (NOV-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
RA   Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
RA   Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
RA   Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
RA   Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
RA   Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
RA   Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
RA   Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
RA   Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
RA   Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
RA   Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
RA   Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
RA   Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
RA   Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
RA   Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
RA   Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
RA   Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
RA   Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
RA   Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
RA   Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
RA   Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
RA   Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
RA   Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
RA   Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
RA   Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
RA   Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
RA   Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
RA   Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
RA   Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
RA   Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
RA   Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
RA   Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
RA   O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
RA   Khan A.S., Lane L., Tilahun Y., Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-103.
RC   TISSUE=Foreskin;
RX   PubMed=2911585; DOI=10.1073/pnas.86.1.99;
RA   Keyse S.M., Tyrrell R.M.;
RT   "Heme oxygenase is the major 32-kDa stress protein induced in human
RT   skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium
RT   arsenite.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:99-103(1989).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-7.
RX   PubMed=2537723; DOI=10.1111/j.1432-1033.1989.tb14583.x;
RA   Shibahara S., Sato M., Muller R.M., Yoshida T.;
RT   "Structural organization of the human heme oxygenase gene and the
RT   function of its promoter.";
RL   Eur. J. Biochem. 179:557-563(1989).
RN   [7]
RP   INVOLVEMENT IN HMOX1D.
RX   PubMed=9884342; DOI=10.1172/JCI4165;
RA   Yachie A., Niida Y., Wada T., Igarashi N., Kaneda H., Toma T.,
RA   Ohta K., Kasahara Y., Koizumi S.;
RT   "Oxidative stress causes enhanced endothelial cell injury in human
RT   heme oxygenase-1 deficiency.";
RL   J. Clin. Invest. 103:129-135(1999).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [9]
RP   REVIEW ON ANTIAPOPTOTIC FUNCTION.
RX   PubMed=20055707; DOI=10.1146/annurev.pharmtox.010909.105600;
RA   Gozzelino R., Jeney V., Soares M.P.;
RT   "Mechanisms of cell protection by heme oxygenase-1.";
RL   Annu. Rev. Pharmacol. Toxicol. 50:323-354(2010).
RN   [10]
RP   TISSUE SPECIFICITY.
RX   PubMed=20855888; DOI=10.1074/jbc.M110.170324;
RA   Datta D., Banerjee P., Gasser M., Waaga-Gasser A.M., Pal S.;
RT   "CXCR3-B can mediate growth-inhibitory signals in human renal cancer
RT   cells by down-regulating the expression of heme oxygenase-1.";
RL   J. Biol. Chem. 285:36842-36848(2010).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-229, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   SUBCELLULAR LOCATION.
RX   PubMed=22419571; DOI=10.3324/haematol.2012.063651;
RA   Gottlieb Y., Truman M., Cohen L.A., Leichtmann-Bardoogo Y.,
RA   Meyron-Holtz E.G.;
RT   "Endoplasmic reticulum anchored heme-oxygenase 1 faces the cytosol.";
RL   Haematologica 97:1489-1493(2012).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.08 ANGSTROMS).
RX   PubMed=10467099; DOI=10.1038/12319;
RA   Schuller D.J., Wilks A., Ortiz de Montellano P.R., Poulos T.L.;
RT   "Crystal structure of human heme oxygenase-1.";
RL   Nat. Struct. Biol. 6:860-867(1999).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (1.55 ANGSTROMS) OF 1-233 OF MUTANT ALA-140,
RP   HEME-BINDING SITES, AND MUTAGENESIS OF ASP-140.
RX   PubMed=12842469; DOI=10.1016/S0022-2836(03)00578-3;
RA   Lad L., Wang J., Li H., Friedman J., Bhaskar B.,
RA   Ortiz de Montellano P.R., Poulos T.L.;
RT   "Crystal structures of the ferric, ferrous, and ferrous-NO forms of
RT   the Asp140Ala mutant of human heme oxygenase-1: catalytic
RT   implications.";
RL   J. Mol. Biol. 330:527-538(2003).
CC   -!- FUNCTION: Heme oxygenase cleaves the heme ring at the alpha
CC       methene bridge to form biliverdin. Biliverdin is subsequently
CC       converted to bilirubin by biliverdin reductase. Under
CC       physiological conditions, the activity of heme oxygenase is
CC       highest in the spleen, where senescent erythrocytes are
CC       sequestrated and destroyed. Exhibits cytoprotective effects since
CC       excess of free heme sensitizes cells to undergo apoptosis.
CC   -!- CATALYTIC ACTIVITY: Protoheme + 3 [reduced NADPH--hemoprotein
CC       reductase] + 3 O(2) = biliverdin + Fe(2+) + CO + 3 [oxidized
CC       NADPH--hemoprotein reductase] + 3 H(2)O.
CC       {ECO:0000250|UniProtKB:O48782}.
CC   -!- INTERACTION:
CC       Q9NUX5:POT1; NbExp=2; IntAct=EBI-2806151, EBI-752420;
CC   -!- SUBCELLULAR LOCATION: Microsome {ECO:0000269|PubMed:22419571}.
CC       Endoplasmic reticulum membrane {ECO:0000269|PubMed:22419571};
CC       Peripheral membrane protein {ECO:0000269|PubMed:22419571};
CC       Cytoplasmic side {ECO:0000269|PubMed:22419571}.
CC   -!- TISSUE SPECIFICITY: Expressed at higher levels in renal cancer
CC       tissue than in normal tissue (at protein level).
CC       {ECO:0000269|PubMed:20855888}.
CC   -!- INDUCTION: Heme oxygenase 1 activity is highly inducible by its
CC       substrate heme and by various non-heme substances such as heavy
CC       metals, bromobenzene, endotoxin, oxidizing agents and UVA.
CC   -!- DISEASE: Heme oxygenase 1 deficiency (HMOX1D) [MIM:614034]: A
CC       disease characterized by impaired stress hematopoiesis, resulting
CC       in marked erythrocyte fragmentation and intravascular hemolysis,
CC       coagulation abnormalities, endothelial damage, and iron deposition
CC       in renal and hepatic tissues. Clinical features include persistent
CC       hemolytic anemia, asplenia, nephritis, generalized erythematous
CC       rash, growth retardation and hepatomegaly.
CC       {ECO:0000269|PubMed:9884342}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the heme oxygenase family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/hmox1/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X06985; CAA30045.1; -; mRNA.
DR   EMBL; CR456505; CAG30391.1; -; mRNA.
DR   EMBL; AY460337; AAR23262.1; -; Genomic_DNA.
DR   EMBL; Z82244; CAB05109.1; -; Genomic_DNA.
DR   EMBL; M23041; AAA50403.1; -; mRNA.
DR   EMBL; X14782; CAA32886.1; -; Genomic_DNA.
DR   CCDS; CCDS13914.1; -.
DR   PIR; S00325; S00325.
DR   RefSeq; NP_002124.1; NM_002133.2.
DR   UniGene; Hs.517581; -.
DR   UniGene; Hs.727017; -.
DR   PDB; 1N3U; X-ray; 2.58 A; A/B=1-233.
DR   PDB; 1N45; X-ray; 1.50 A; A/B=1-233.
DR   PDB; 1NI6; X-ray; 2.10 A; A/B/C/D=1-224.
DR   PDB; 1OYK; X-ray; 2.59 A; A/B=1-233.
DR   PDB; 1OYL; X-ray; 1.59 A; A/B=1-233.
DR   PDB; 1OZE; X-ray; 2.19 A; A/B=1-233.
DR   PDB; 1OZL; X-ray; 1.58 A; A/B=1-233.
DR   PDB; 1OZR; X-ray; 1.74 A; A/B=1-233.
DR   PDB; 1OZW; X-ray; 1.55 A; A/B=1-233.
DR   PDB; 1S13; X-ray; 2.29 A; A/B=1-233.
DR   PDB; 1S8C; X-ray; 2.19 A; A/B/C/D=1-233.
DR   PDB; 1T5P; X-ray; 2.11 A; A/B=1-233.
DR   PDB; 1TWN; X-ray; 2.20 A; A/B=1-233.
DR   PDB; 1TWR; X-ray; 2.10 A; A/B=1-233.
DR   PDB; 1XJZ; X-ray; 1.88 A; A/B=1-233.
DR   PDB; 1XK0; X-ray; 2.18 A; A/B=1-233.
DR   PDB; 1XK1; X-ray; 2.08 A; A/B=1-233.
DR   PDB; 1XK2; X-ray; 2.20 A; A/B=1-233.
DR   PDB; 1XK3; X-ray; 2.08 A; A/B=1-233.
DR   PDB; 3CZY; X-ray; 1.54 A; A/B=1-233.
DR   PDB; 3HOK; X-ray; 2.19 A; A/B=1-233.
DR   PDB; 3K4F; X-ray; 2.17 A; A/B=1-233.
DR   PDB; 3TGM; X-ray; 2.85 A; A/B=1-233.
DR   PDB; 4WD4; X-ray; 2.95 A; A/B/C/D=1-288.
DR   PDB; 5BTQ; X-ray; 2.08 A; A/B=1-233.
DR   PDBsum; 1N3U; -.
DR   PDBsum; 1N45; -.
DR   PDBsum; 1NI6; -.
DR   PDBsum; 1OYK; -.
DR   PDBsum; 1OYL; -.
DR   PDBsum; 1OZE; -.
DR   PDBsum; 1OZL; -.
DR   PDBsum; 1OZR; -.
DR   PDBsum; 1OZW; -.
DR   PDBsum; 1S13; -.
DR   PDBsum; 1S8C; -.
DR   PDBsum; 1T5P; -.
DR   PDBsum; 1TWN; -.
DR   PDBsum; 1TWR; -.
DR   PDBsum; 1XJZ; -.
DR   PDBsum; 1XK0; -.
DR   PDBsum; 1XK1; -.
DR   PDBsum; 1XK2; -.
DR   PDBsum; 1XK3; -.
DR   PDBsum; 3CZY; -.
DR   PDBsum; 3HOK; -.
DR   PDBsum; 3K4F; -.
DR   PDBsum; 3TGM; -.
DR   PDBsum; 4WD4; -.
DR   PDBsum; 5BTQ; -.
DR   ProteinModelPortal; P09601; -.
DR   SMR; P09601; -.
DR   BioGrid; 109405; 32.
DR   IntAct; P09601; 11.
DR   STRING; 9606.ENSP00000216117; -.
DR   BindingDB; P09601; -.
DR   ChEMBL; CHEMBL2823; -.
DR   DrugBank; DB07342; 1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone.
DR   DrugBank; DB02468; 12-Phenylheme.
DR   DrugBank; DB03906; 2-Phenylheme.
DR   DrugBank; DB02073; Biliverdine Ix Alpha.
DR   DrugBank; DB01942; Formic Acid.
DR   DrugBank; DB00157; NADH.
DR   DrugBank; DB04912; Stannsoporfin.
DR   DrugBank; DB04803; Verdoheme.
DR   DrugBank; DB00163; Vitamin E.
DR   GuidetoPHARMACOLOGY; 1441; -.
DR   iPTMnet; P09601; -.
DR   PhosphoSitePlus; P09601; -.
DR   BioMuta; HMOX1; -.
DR   DMDM; 123446; -.
DR   EPD; P09601; -.
DR   PaxDb; P09601; -.
DR   PeptideAtlas; P09601; -.
DR   PRIDE; P09601; -.
DR   DNASU; 3162; -.
DR   Ensembl; ENST00000216117; ENSP00000216117; ENSG00000100292.
DR   GeneID; 3162; -.
DR   KEGG; hsa:3162; -.
DR   CTD; 3162; -.
DR   DisGeNET; 3162; -.
DR   GeneCards; HMOX1; -.
DR   HGNC; HGNC:5013; HMOX1.
DR   HPA; CAB017444; -.
DR   HPA; HPA000635; -.
DR   MalaCards; HMOX1; -.
DR   MIM; 141250; gene.
DR   MIM; 614034; phenotype.
DR   neXtProt; NX_P09601; -.
DR   OpenTargets; ENSG00000100292; -.
DR   PharmGKB; PA29341; -.
DR   eggNOG; KOG4480; Eukaryota.
DR   eggNOG; COG5398; LUCA.
DR   GeneTree; ENSGT00390000017673; -.
DR   HOGENOM; HOG000233221; -.
DR   HOVERGEN; HBG005982; -.
DR   InParanoid; P09601; -.
DR   KO; K00510; -.
DR   OMA; TKKAHTM; -.
DR   OrthoDB; EOG091G0AS0; -.
DR   PhylomeDB; P09601; -.
DR   TreeFam; TF314786; -.
DR   BioCyc; MetaCyc:HS02027-MONOMER; -.
DR   BRENDA; 1.14.99.3; 2681.
DR   Reactome; R-HSA-189483; Heme degradation.
DR   Reactome; R-HSA-6785807; Interleukin-4 and 13 signaling.
DR   Reactome; R-HSA-917937; Iron uptake and transport.
DR   SIGNOR; P09601; -.
DR   EvolutionaryTrace; P09601; -.
DR   GeneWiki; HMOX1; -.
DR   GenomeRNAi; 3162; -.
DR   PRO; PR:P09601; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   Bgee; ENSG00000100292; -.
DR   CleanEx; HS_HMOX1; -.
DR   ExpressionAtlas; P09601; baseline and differential.
DR   Genevisible; P09601; HS.
DR   GO; GO:0005901; C:caveola; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; TAS:BHF-UCL.
DR   GO; GO:0016020; C:membrane; TAS:ProtInc.
DR   GO; GO:0005730; C:nucleolus; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; ISS:BHF-UCL.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; ISS:BHF-UCL.
DR   GO; GO:0020037; F:heme binding; IDA:BHF-UCL.
DR   GO; GO:0004392; F:heme oxygenase (decyclizing) activity; IDA:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004630; F:phospholipase D activity; IEA:Ensembl.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0004871; F:signal transducer activity; IMP:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; TAS:BHF-UCL.
DR   GO; GO:0008219; P:cell death; ISS:BHF-UCL.
DR   GO; GO:0006879; P:cellular iron ion homeostasis; IMP:CACAO.
DR   GO; GO:0071243; P:cellular response to arsenic-containing substance; IEA:Ensembl.
DR   GO; GO:0071276; P:cellular response to cadmium ion; IEA:Ensembl.
DR   GO; GO:0072719; P:cellular response to cisplatin; IEA:Ensembl.
DR   GO; GO:0034605; P:cellular response to heat; IMP:UniProtKB.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEP:UniProtKB.
DR   GO; GO:0031670; P:cellular response to nutrient; IEA:Ensembl.
DR   GO; GO:0001935; P:endothelial cell proliferation; TAS:BHF-UCL.
DR   GO; GO:0034101; P:erythrocyte homeostasis; IMP:BHF-UCL.
DR   GO; GO:0007588; P:excretion; IC:BHF-UCL.
DR   GO; GO:0042167; P:heme catabolic process; IDA:BHF-UCL.
DR   GO; GO:0006788; P:heme oxidation; IDA:BHF-UCL.
DR   GO; GO:0035556; P:intracellular signal transduction; TAS:BHF-UCL.
DR   GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IEA:Ensembl.
DR   GO; GO:0055072; P:iron ion homeostasis; IDA:BHF-UCL.
DR   GO; GO:0097421; P:liver regeneration; IEA:Ensembl.
DR   GO; GO:0034383; P:low-density lipoprotein particle clearance; TAS:BHF-UCL.
DR   GO; GO:0043392; P:negative regulation of DNA binding; IEA:Ensembl.
DR   GO; GO:1904036; P:negative regulation of epithelial cell apoptotic process; IEA:Ensembl.
DR   GO; GO:1902042; P:negative regulation of extrinsic apoptotic signaling pathway via death domain receptors; IMP:BHF-UCL.
DR   GO; GO:0002686; P:negative regulation of leukocyte migration; TAS:BHF-UCL.
DR   GO; GO:0016242; P:negative regulation of macroautophagy; IEA:Ensembl.
DR   GO; GO:0032764; P:negative regulation of mast cell cytokine production; IEA:Ensembl.
DR   GO; GO:0043305; P:negative regulation of mast cell degranulation; IEA:Ensembl.
DR   GO; GO:0010656; P:negative regulation of muscle cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0043433; P:negative regulation of sequence-specific DNA binding transcription factor activity; IEA:Ensembl.
DR   GO; GO:0048662; P:negative regulation of smooth muscle cell proliferation; IDA:UniProtKB.
DR   GO; GO:1904706; P:negative regulation of vascular smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0097755; P:positive regulation of blood vessel diameter; IC:BHF-UCL.
DR   GO; GO:0045080; P:positive regulation of chemokine biosynthetic process; TAS:BHF-UCL.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IMP:UniProtKB.
DR   GO; GO:0016239; P:positive regulation of macroautophagy; IEA:Ensembl.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IDA:UniProtKB.
DR   GO; GO:0051260; P:protein homooligomerization; IDA:UniProtKB.
DR   GO; GO:0045765; P:regulation of angiogenesis; TAS:BHF-UCL.
DR   GO; GO:0008217; P:regulation of blood pressure; IEA:Ensembl.
DR   GO; GO:0051090; P:regulation of sequence-specific DNA binding transcription factor activity; ISS:BHF-UCL.
DR   GO; GO:0034395; P:regulation of transcription from RNA polymerase II promoter in response to iron; IEA:Ensembl.
DR   GO; GO:0043619; P:regulation of transcription from RNA polymerase II promoter in response to oxidative stress; ISS:BHF-UCL.
DR   GO; GO:0043627; P:response to estrogen; IEA:Ensembl.
DR   GO; GO:0042542; P:response to hydrogen peroxide; ISS:BHF-UCL.
DR   GO; GO:0035094; P:response to nicotine; IDA:BHF-UCL.
DR   GO; GO:0006979; P:response to oxidative stress; IMP:BHF-UCL.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; IEA:Ensembl.
DR   GO; GO:0014806; P:smooth muscle hyperplasia; TAS:BHF-UCL.
DR   GO; GO:0002246; P:wound healing involved in inflammatory response; IMP:BHF-UCL.
DR   CDD; cd00232; HemeO; 1.
DR   Gene3D; 1.20.910.10; -; 1.
DR   InterPro; IPR002051; Haem_Oase.
DR   InterPro; IPR016053; Haem_Oase-like.
DR   InterPro; IPR016084; Haem_Oase-like_multi-hlx.
DR   InterPro; IPR018207; Haem_oxygenase_CS.
DR   PANTHER; PTHR10720; PTHR10720; 1.
DR   Pfam; PF01126; Heme_oxygenase; 1.
DR   PIRSF; PIRSF000343; Haem_Oase; 1.
DR   PRINTS; PR00088; HAEMOXYGNASE.
DR   SUPFAM; SSF48613; SSF48613; 1.
DR   PROSITE; PS00593; HEME_OXYGENASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Apoptosis; Complete proteome; Endoplasmic reticulum;
KW   Heme; Iron; Membrane; Metal-binding; Microsome; Oxidoreductase;
KW   Phosphoprotein; Polymorphism; Reference proteome.
FT   CHAIN         1    288       Heme oxygenase 1.
FT                                /FTId=PRO_0000209687.
FT   METAL        25     25       Iron (heme axial ligand).
FT   BINDING      18     18       Heme.
FT   BINDING     134    134       Heme.
FT   BINDING     183    183       Heme.
FT   MOD_RES     229    229       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   VARIANT       7      7       D -> H (in dbSNP:rs2071747).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_019165.
FT   VARIANT     106    106       P -> L (in dbSNP:rs9282702).
FT                                /FTId=VAR_022156.
FT   MUTAGEN     140    140       D->A: Inactive as a heme oxygenase but
FT                                active as a peroxidase.
FT                                {ECO:0000269|PubMed:12842469}.
FT   HELIX         6      8       {ECO:0000244|PDB:1NI6}.
FT   HELIX        13     20       {ECO:0000244|PDB:1N45}.
FT   HELIX        22     30       {ECO:0000244|PDB:1N45}.
FT   HELIX        32     38       {ECO:0000244|PDB:1N45}.
FT   HELIX        44     68       {ECO:0000244|PDB:1N45}.
FT   TURN         72     74       {ECO:0000244|PDB:1N45}.
FT   HELIX        75     77       {ECO:0000244|PDB:1N45}.
FT   HELIX        80     83       {ECO:0000244|PDB:1N45}.
FT   HELIX        86     97       {ECO:0000244|PDB:1N45}.
FT   HELIX       101    103       {ECO:0000244|PDB:1N45}.
FT   HELIX       109    124       {ECO:0000244|PDB:1N45}.
FT   HELIX       126    128       {ECO:0000244|PDB:1N45}.
FT   HELIX       129    155       {ECO:0000244|PDB:1N45}.
FT   STRAND      159    161       {ECO:0000244|PDB:3CZY}.
FT   HELIX       165    167       {ECO:0000244|PDB:1N45}.
FT   HELIX       175    188       {ECO:0000244|PDB:1N45}.
FT   HELIX       193    220       {ECO:0000244|PDB:1N45}.
SQ   SEQUENCE   288 AA;  32819 MW;  AB47827778694064 CRC64;
     MERPQPDSMP QDLSEALKEA TKEVHTQAEN AEFMRNFQKG QVTRDGFKLV MASLYHIYVA
     LEEEIERNKE SPVFAPVYFP EELHRKAALE QDLAFWYGPR WQEVIPYTPA MQRYVKRLHE
     VGRTEPELLV AHAYTRYLGD LSGGQVLKKI AQKALDLPSS GEGLAFFTFP NIASATKFKQ
     LYRSRMNSLE MTPAVRQRVI EEAKTAFLLN IQLFEELQEL LTHDTKDQSP SRAPGLRQRA
     SNKVQDSAPV ETPRGKPPLN TRSQAPLLRW VLTLSFLVAT VAVGLYAM
//
